New treatment for patients with multiple myeloma will now be available on the NHS in England. Darzalex was approved by NICE in combination with two other drugs, bortezomib and dexamethasone, after the treatment was found to extend the time that patients lived without their cancer getting worse. The combination will be paid for through the Cancer Drugs Fundand will
A new study conducted by researchers from the University of Southern California in Los Angeles, explains how aerobic and resistance exercise can increase life expectancy for patients who have successfully completed breast cancer treatment. According to National Cancer Institute estimates, in 2017 there were approximately 252,710 new diagnoses of breast cancer in the United States.
Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib
Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C. Eli Lilly’s Lartruvo was approved for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues within
Novartis has entered a clinical research collaboration with Bristol-Myers Squibb to investigate the safety, tolerability, and efficacy of Mekinist in combination with Opdivo and Opdivo + Yervoy regimen. The cancer treatments are being used as a potential option for metastatic colorectal cancer in patients with microsatellite stable tumours where the tumours are proficient in mismatch
A Cancer Research UK funded study published in the British Journal of General Practice has found more than one third (34%) of patients are diagnosed with cancer as an emergency in England had not visited their GP beforehand, which is hindering their chances of achieving the best treatment outcomes. Data collected from more than 4,600
Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from
The human body has a built-in army to help combat against disease, the immune system. In addition to fighting off bacteria and viruses it can also help combat tumours. That’s why researchers are attempting to rally these cells to treat cancer, leading to some significant advances being made over previous years.
A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new treatments” – Professor Peter Johnson, Cancer Research UK. Patients with
Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines. Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accelerator) machines, as part of a £130-million investment in radiotherapy
